Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab + nivolumab versus regorafenib or trifluridine + tipiracil in later-line metastatic colorectal cancer
2021-004285-35Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in metastatic colorectal adenocarcinoma (mCRC) comparing Relatlimab + nivolumab fixed-dose combination, Regorafenib and Trifluridine + tipiracil (3 arms). Primary endpoint: Overall Survival. Started Mar 2022; status: active.
02
Drugs
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2021-004285-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004285-35.